NCT01138488View on ClinicalTrials.gov

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec/insulin aspart

Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).

Trial Locations (1)

30173

Novo Nordisk Investigational Site, Hanover

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
collaborator

HNEC TEST

UNKNOWN

lead

Novo Nordisk A/S

INDUSTRY

NCT01138488 - A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter